Key result
Prospective chronic device studies detected clinically significant adverse events in 2.2% of leads compared to 0.5% detected by return product analysis, with survival rates differing by 2 years.
Why the study?
Does prospective chronic device monitoring improve the detection of ICD lead failures compared to returned product analysis?
Observational
Does prospective chronic device monitoring improve the detection of ICD lead failures compared to returned product analysis?
Prospective chronic device studies are superior to returned product analysis for detecting ICD lead failures and monitoring long-term device performance.
Answers are grounded in this paper and cite their sources.
May improve ICD lead failure detection over returned product analysis; hypothesis-generating for long-term device surveillance.
Monitoring and reporting mechanisms are vital tools for clinicians to assess ICD system performance over time for optimal patient care. This article explores the various reporting mechanisms available to the clinician, both historical and current, and compares and contrasts two such methods. The lead survival rates obtained by return product analysis (RPA) are compared with those from an ongoing prospective chronic study that actively follows patients for clinical ICD system failures (Tachyarrhythmia Chronic Systems Study [TCSS]). Examination of available data shows that a prospective study such as the TCSS is capable of detecting clinically significant adverse events in 2.2% of the 3,958 leads followed. By comparison, RPA-based monitoring of the same leads detects "out of specification" events in 0.5% of the 78,571 leads followed. Statistical analyses of two separate families of leads (RV leads and SQ Patch leads) show that survival rates obtained by the two methods begin to differ at approximately 2 years of implant experience, with 95% confidence intervals no longer overlapping at 3 years. The authors conclude that prospective chronic device studies are a superior tool for the ongoing monitoring of implanted device performance compared to RPA-based reports.
No takes yet. Share an insight, caveat, or question.
PRATT et al. (2000) conducted an observational in ICD system performance. Prospective chronic study (TCSS) vs. Return product analysis (RPA) was evaluated on Clinically significant adverse events or out of specification events. Prospective chronic device studies detected clinically significant adverse events in 2.2% of leads compared to 0.5% detected by return product analysis, with survival rates differing by 2 years.
Synapse has enriched 10 related papers. Consider them for comparative context: